HC Wainwright & Co. Reiterates Buy on Kiora Pharmaceuticals, Maintains $3.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Kiora Pharmaceuticals (NASDAQ:KPRX) and maintained a price target of $3.5.
November 13, 2023 | 3:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kiora Pharmaceuticals maintains a Buy rating and a $3.5 price target from HC Wainwright & Co. analyst Yi Chen.
The reiteration of a Buy rating and the maintenance of a price target by a reputable analyst like Yi Chen can instill confidence in investors and potentially lead to a positive short term impact on KPRX's stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100